Results 201 to 210 of about 39,541 (234)

Fezolinetant (Veozah) for Menopausal Vasomotor Symptoms

The Medical Letter on Drugs and Therapeutics, 2023
Fezolinetant (Veozah – Astellas), a first-in-class neurokinin 3 (NK3) receptor antagonist, has been approved by the FDA for treatment of moderate to severe vasomotor symptoms (VMS) due to menopause.
openaire   +2 more sources

Managing vasomotor symptoms effectively without hormones

Climacteric, 2020
Vasomotor symptoms (hot flushes and/or night sweats) affect approximately 80% of women over the menopause transition and can affect quality of life, productivity, and relationships. Vasomotor symptoms are the main reason for seeking treatment during the menopausal transition. Although menopausal hormone therapy (MHT) is effective for symptom management,
C. A. McCormick, A. Brennan, M. Hickey
openaire   +2 more sources

Vasomotor and Related Menopause Symptoms

Clinical Obstetrics & Gynecology, 2018
Vasomotor symptoms are the most common manifestation of the menopause transition and postmenopausal phases of reproductive life. They interfere not only in quality of life, but also contribute to sleep and mood disturbances that potentially compromise home and work effectiveness.
openaire   +2 more sources

Vasomotor symptoms and mortality

Menopause, 2009
The purpose of this study was to examine the associations of vasomotor symptoms with risk of all-cause, cardiovascular disease (CVD), and coronary heart disease (CHD) mortality in community-dwelling older women, with a mean age of 69 years.This prospective population-based study included 867 postmenopausal women who provided lifestyle and menopause ...
Johan, Svartberg, Denise, von Mühlen, Donna, Kritz-Silverstein, Elizabeth, Barrett-Connor   +3 more
openaire   +2 more sources

Non-hormonal management of vasomotor symptoms

Climacteric, 2013
Vasomotor symptoms are the most common indication for the prescription of hormone replacement therapy since it is effective in over 80% of cases. In 1995, 37% of American women took hormone replacement therapy, principally for this purpose. However, following the publication of results from the Women's Health Initiative, as many as half of these women ...
J, Sassarini, M A, Lumsden
openaire   +2 more sources

Vasomotor Symptoms: Clinical Management

2019
Vasomotor symptoms (VMS) or “hot flashes” are the most common complaint during the menopausal transition. Despite they affect quality of life and appear to be linked to cardiovascular, bone, and brain health, only a minor seek medical attention for treatment.
Maria Celeste Osorio-Wender, Mona Lúcia Dall’Agno   +1 more
openaire   +1 more source

Acupuncture for vasomotor menopausal symptoms

Menopause, 2009
The aim of this study was to critically assess whether acupuncture therapy reduces vasomotor menopausal symptoms and to evaluate the adverse effects of acupuncture therapy on the basis of the results of randomized controlled trials (RCTs).Nineteen electronic databases, including English, Korean, Japanese, and Chinese databases, were systematically ...
Seung-Hun, Cho, Wei-Wan, Whang
openaire   +2 more sources

Acupuncture Relieves Menopause-Related Vasomotor Symptoms

AJN, American Journal of Nursing, 2016
According to this study:Use of acupuncture reduced the number of hot flashes and other vasomotor symptoms and improved quality of life in peri- and postmenopausal women.These clinical benefits persisted for at least six months.
openaire   +2 more sources

Vasomotor symptoms and cardiovascular disease risk

Climacteric, 2011
Although the exact etiology of hot flushes and night sweats has not been fully clarified, the intriguing question whether vasomotor symptoms (VMS) are markers of coronary artery disease risk has been evaluated in several studies. Surrogate metabolic and hemodynamic parameters point at adverse alterations in flushers, but the results related to clinical
openaire   +2 more sources

Nonhormonal treatments for vasomotor symptoms

Current Opinion in Obstetrics & Gynecology
Purpose of the review Vasomotor symptoms or hot flashes are reported by 80% of women and have a median duration of 7 years. About 25–30% of women have severe enough symptoms that activities of daily living and workplace productivity are compromised.
Laura Zalles, Nanette Santoro
openaire   +1 more source